Log in to search using one of your social media accounts:

 

Perioperative Aspirin Might Benefit Patients with Prior PCI
Perioperative aspirin seems beneficial for high-risk patients undergoing noncardiac surgery who've previously undergone percutaneous coronary intervention (PCI), according to a subanalysis from the POISE... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 14, 2017 Category: Primary Care Source Type: news

Aspirin can prevent heart attacks after noncardiac surgery in patients with prior PCI
(University of Alberta Faculty of Medicine& Dentistry) A Canadian-led study has found that perioperative aspirin can prevent heart-related complications after major noncardiac surgery in patients with previous percutaneous coronary intervention (PCI) such as an angioplasty or stent. The study found that for every 1,000 patients with PCI, giving them aspirin at the time of noncardiac surgery would prevent 59 heart attacks and cause eight major bleeding events. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 14, 2017 Category: International Medicine & Public Health Source Type: news

Study: PCI Appears No Better Than Sham Procedure in Patients with Stable Angina (FREE)
By Kelly Young Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS Percutaneous coronary intervention (PCI) didn't improve exercise time relative to a sham procedure in patients with stable angina and severe coronary stenosis. Findings from the ORBITA study were published in the Lancet and presented at the … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 3, 2017 Category: Primary Care Source Type: news

Analysis Shows Better Health Outcomes and Cost Effectiveness for Coronary Intervention Using Abbott's Fractional Flow Reserve (FFR) Diagnostic in Patients with Stable Coronary Artery Disease
After three years, patients who underwent FFR-guided percutaneous coronary intervention (PCI) in combination with medical therapy had significantly fewer major adverse cardiac events compared to patients who received medical therapy alone (Source: Abbott.com)
Source: Abbott.com - November 2, 2017 Category: Pharmaceuticals Source Type: news

Cordis Comes Back for Another Stent
Cordis is getting back into the coronary stent game. The company, which is now owned by Cardinal Health, landed exclusive rights to sell Medinol's coronary stent portfolio in the U.S. Milpitas, CA-based Cordis is already selling Medinol's NIRxcell cobalt-chromium bare-metal stent and, assuming FDA approves Medinol's EluNIR drug-eluting stent (DES), Cordis will distribute it as well. Medinol is based in Israel. In addition to the Medinol agreement, Cordis recently launched the Tryton Side Branch Stent and two percutaneous transluminal coronary angioplasty (PTCA) balloon catheters. The Medinol agreement, along with the ...
Source: MDDI - October 31, 2017 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Source Type: news

Should patients with cardiogenic shock receive culprit lesion only PCI or multivessel PCI?
(Cardiovascular Research Foundation) Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found that an initial strategy of culprit lesion only percutaneous coronary intervention (PCI) reduces the composite of 30-day mortality and/or severe renal failure in patients with multivessel disease and cardiogenic shock complicating acute myocardial infarction. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 31, 2017 Category: International Medicine & Public Health Source Type: news

SCAI launches educational initiative as nation shifts to value-based healthcare
(Society for Cardiovascular Angiography and Interventions) The Society for Cardiovascular Angiography and Interventions announced today the launch of TRAnsition for VALUE, a multi-faceted educational initiative supported by Medtronic, to inform cardiologists, hospital administrators, and cath lab staff about the benefits of expanding the adoption of transradial (wrist access) percutaneous coronary intervention (PCI) in the US. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 30, 2017 Category: International Medicine & Public Health Source Type: news

FDA clears expansion of CeloNova ’s nano-coated coronary stent trial
CeloNova Biosciences said today that the FDA approved an expansion of the on-going clinical trial for its Cobra PzF nano-coated coronary stent with 14-day dual antiplatelet therapy in complex patients, like people who are at a high risk of bleeding. The company touted its Cobra Reduce trial as the first randomized control trial to study 14-day DAPT following percutaneous coronary intervention. Get the full story at our sister site, Drug Delivery Business News. The post FDA clears expansion of CeloNova’s nano-coated coronary stent trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 26, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Stents Vascular CeloNova BioSciences Source Type: news

Registry data examines oral anticoagulant use in women, adverse events after PCI discharge
(American College of Cardiology) Data from the American College of Cardiology's National Cardiovascular Data Registry was the source of several published studies in recent months, including a study on predicting 30-day readmission rates for patients undergoing percutaneous coronary intervention and a study that found women were less likely to use oral anticoagulants to treat atrial fibrillation. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 5, 2017 Category: International Medicine & Public Health Source Type: news

Andreas Roland Gruentzig, the Man Andreas Roland Gruentzig, the Man
A fascinating profile of Andreas Gruentzig, the renowned cardiologist who first developed balloon angioplasty, and is considered the father of modern-day percutaneous coronary intervention.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 26, 2017 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

MassDevice.com +5 | The top 5 medtech stories for September 20, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. The 10 largest medical device companies in the world Mergers & acquisitions continue to change the medical device landscape, as reflected in Medical Design & Outsourcing’s new Big 100 list. We pulled financial reg...
Source: Mass Device - September 20, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Reva Medical ’s Fantom bioresorbable, drug-eluting vascular scaffold succeeds at 6 months
As some companies have worked to improve drug-eluting stents by making them bioresorbable, some voices in the coronary intervention space have expressed concern over the rates of late stent thrombosis and repeat percutaneous coronary intervention seen with the devices. In a study published in the September issue of JACC: Cardiovascular Intervention, Reva Medical‘s (ASX:RVA) Fantom coronary bioresorbable vascular scaffold succeeded after six months. The device was designed to address challenges like strut size and expansion capacity, the researchers wrote. Get the full story at our sister site, Drug Delivery...
Source: Mass Device - September 20, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Drug-Device Combinations Drug-Eluting Stents Pharmaceuticals Wall Street Beat Abbott Reva Medical Inc. Source Type: news

Firefighter ™ PTCA Balloon Catheter Receives Regulatory Approval in South Korea
(Source: Microport News Release)
Source: Microport News Release - September 12, 2017 Category: Medical Devices Source Type: news

Study examines use of systolic blood pressure at time of primary percutaneous coronary intervention
(Society for Cardiovascular Angiography and Interventions) Researchers have led a retrospective single-center study examining simple hemodynamic parameters obtained at the time of cardiac catheterization to predict in-hospital mortality following ST-elevation myocardial infarction (STEMI). Current 30-day mortality rates for patients with STEMI range from 2.5% to 10%, and 10.5%-24% of those patients require mechanical hemodynamic support. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 11, 2017 Category: International Medicine & Public Health Source Type: news

BLS Crews in Paris Detect Atypical STEMI via 12-Lead ECG
By Jonathan Gonzva, MD; Laure Alhanati, MD; Stéphane Dubourdieu, MD; Daniel Jost, MD; Hugues Lefort, MD; Benoît Frattini, MD & Jean-Pierre Tourtier, MD A 61-year-old man calls the Paris Fire Brigade dispatch center with a complaint of dental pain. He reports feeling pain in the jaw for the past 35 minutes, which he says now extends to the armpits. He also reports that he experienced the same feeling the day before. The patient's age and hyperlipidemia were his only cardiovascular risk factors with atorvastatine and budesonide as the usual treatments. The physician stationed at the dispatch cen...
Source: JEMS Patient Care - September 7, 2017 Category: Emergency Medicine Tags: International Cardiac & Resuscitation Columns Patient Care Source Type: news

Rethinking dual antiplatelet guidelines in acute coronary syndrome? (CHANGE-DAPT)
(European Society of Cardiology) New research presented at ESC Congress today1 suggests that for acute coronary syndrome (ACS) patients who require percutaneous coronary intervention (PCI), treatment according to contemporary guidelines for dual anti-platelet therapy (DAPT) could be less preferable than sticking to older guidelines. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 29, 2017 Category: International Medicine & Public Health Source Type: news

Firefighter ™ PTCA Balloon Catheter Gains Regulatory Approval in Argentina
(Source: Microport News Release)
Source: Microport News Release - August 17, 2017 Category: Medical Devices Source Type: news

Angioplasty outcomes almost equal among hospitals
Patients who undergo percutaneous coronary intervention have similar outcomes at different hospitals, researchers said. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 8, 2017 Category: Consumer Health News Source Type: news

Angioplasty Outcomes Almost Equal Among Hospitals
MONDAY, Aug. 7, 2017 -- Patients who have an artery-opening procedure called percutaneous coronary intervention (PCI) have similar outcomes whether they're treated at so-called safety-net or non-safety-net hospitals, researchers say. Safety-net... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 7, 2017 Category: General Medicine Source Type: news

Blacks and Whites Have Similar Outcomes After PCI Blacks and Whites Have Similar Outcomes After PCI
A study designed to look for differing outcomes when black and white U.S. veterans undergo percutaneous coronary intervention (PCI) instead found no differences once confounding factors were taken into account.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - July 25, 2017 Category: Intensive Care Tags: Family Medicine/Primary Care News Source Type: news

Roxwood Medical Announces Agreement with Abbott for Distribution of Products in U.S.
REDWOOD CITY, Calif., July 25, 2017 -- (Healthcare Sales & Marketing Network) -- Roxwood Medical Inc., a leading provider of advanced cardiovascular specialty catheters, today announced it has entered into an exclusive agreement with Abbott for distributi... Devices, Interventional, Cardiology, Distribution Roxwood Medical, Abbott, CenterCross, Percutaneous coronary intervention (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 25, 2017 Category: Pharmaceuticals Source Type: news

Firefighter ™ PTCA Balloon Catheter Gains CFDA Approval
(Source: Microport News Release)
Source: Microport News Release - July 24, 2017 Category: Medical Devices Source Type: news

Bayer ’s Xarelto in Combination with Single Antiplatelet Therapy Receives Positive CHMP Opinion for Treatment of Patients with Atrial Fibrillation requiring oral Anticoagulation and undergoing Percutaneous Coronary Intervention with Stent Placement (for specialized target groups only)
Positive CHMP Opinion is based on data from the Phase IIIb PIONEER AF-PCI study, which demonstrated significantly reduced rates of clinically significant bleeding with Xarelto compared with VKA in patients with non-valvular atrial fibrillation (AF) who require oral anticoagulation and are also receiving antiplatelet therapy after percutaneous coronary intervention (PCI) with stent placement (1) / PIONEER AF-PCI is the first and currently only randomised clinical trial of a non-vitamin K antagonist oral anticoagulant (NOAC) in this patient population / Final decision of European Commission expected by the end of this year (...
Source: Bayer Company News - July 21, 2017 Category: Pharmaceuticals Source Type: news

Heart vessel-clearing procedure can benefit some at age 90 and older
People in their nineties and older represent a tiny but growing fraction of patients who undergo a procedure called percutaneous coronary intervention (PCI) to clear blocked blood vessels in the heart, new research shows. (Source: Reuters: Health)
Source: Reuters: Health - July 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Firefighter ™ PTCA Balloon Dilatation Catheter Gains Regulatory Approval in Brazil
(Source: Microport News Release)
Source: Microport News Release - July 7, 2017 Category: Medical Devices Source Type: news

Prolonged DAPT After PCI: Risk Score Helps Identify Those Most Likely to Be Harmed (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD The DAPT (dual antiplatelet therapy) score helps identify patients for whom prolonged treatment after percutaneous coronary intervention would be harmful, suggests an analysis in the Annals of Internal Medicine. Researchers retrospectively applied … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 13, 2017 Category: Primary Care Source Type: news

No difference in rate of adverse cardiovascular events when comparing anticoagulants
In patients undergoing transradial primary percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (STEMI), there was no significant difference in the rate of a composite of death, myocardial infarction and stroke whether they were anticoagulated with bivalirudin or unfractioned heparin, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 17, 2017 Category: Science Source Type: news

MassDevice.com +5 | The top 5 medtech stories for May 16, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Corindus touts high success rate in CorPath 200 PCI registry study Corindus Vascular Robotics today released post-market findings from the Precision registry study of its CorPath 200 system used during percutaneous coronary int...
Source: Mass Device - May 16, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Abbott recalls heart catheters on balloon sheath issue
Abbott (NYSE:ABT) is recalling some 450,000 coronary catheters on the risk that removing a protective balloon sheath can damage the ballon during angioplasty procedures. In a March 22 letter to customers, Abbot said the recall affects its NC Trek RX and NC Traveler RX coronary dilatation catheters and the NC Tenku RX PTCA balloon catheter. “Product from the identified lots may exhibit difficulty in removing the protective balloon sheath which can result in issues with inflating or deflating the balloon,” Abbott said. “If excessive force is required to remove the balloon sheath, the sheath m...
Source: Mass Device - May 16, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Catheters Food & Drug Administration (FDA) Recalls Regulatory/Compliance Abbott Source Type: news

Abbott Initiates Voluntarily Recall of Specific Lots of Three Coronary Catheters
Abbott has initiated a voluntary recall of specific lots of three catheters: NC Trek RX Coronary Dilatation Catheter, NC Traveler Coronary Dilatation Catheter, and NC Tenku RX PTCA Balloon Catheter. (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 15, 2017 Category: Food Science Source Type: news

Large multicenter study shows high success rate for robotic PCI procedures
Results from the PRECISION trial (Efficacy and Safety Outcomes of Radial- vs Femoral-Access Robotic Percutaneous Coronary Intervention: Final Results of the Multicenter PRECISION Registry) were presented today as a late-breaking clinical trial. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 12, 2017 Category: Science Source Type: news

Blood Vessel-Clearing Procedure Riskier on Weekends: Study
THURSDAY, May 11, 2017 -- Although you often don't have a choice of when you get the heart procedure called percutaneous coronary intervention (PCI), new research suggests that having it done over the weekend may be more risky. The study reported... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 11, 2017 Category: General Medicine Source Type: news

Abiomed dips on missed Q4 earnings, despite sales beat
Share prices for Abiomed (NSDQ:ABMD) dipped today after the company reported fiscal 4th-quarter earnings that missed expectations, despite a top-line gain of nearly 33%. The Danvers, Mass.-based heart pump maker posted profits of $14.9 million, or 33¢ per share, on sales of $124.7 million for the 3 months ended March 31, for a bottom-line increase of 35.5% on sales growth of 32.7% compared with Q4 2016. But analysts on Wall Street were looking for earnings per share of 35¢; Abiomed topped the consensus Street estimate for sales by more than $2 million. Full-year profits were $52.1 million, or $1.17 per share...
Source: Mass Device - May 4, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiac Assist Devices MassDevice Earnings Roundup Wall Street Beat Abiomed Source Type: news

MassDevice.com +5 | The top 5 medtech stories for April 21, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Beaver-Visitec picks up Malosa Medical Beaver-Visitec said today it acquired U.K.-based single-use ophthalmology surgical instrument maker Malosa Medical for an undisclosed amount. Malosa Medical has a portfolio of more than 40...
Source: Mass Device - April 21, 2017 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Abbott issues select recall for NC coronary dilation & balloon caths
Abbott (NYSE:ABT) has issued an urgent field safety notice looking to recall select coronary dilation and balloon catheters over issues with inflating and deflating the balloons. The company said it is recalling specific lots of the NC Trek RX coronary dilation catheter, the NC Traveler RX coronary dilation catheter and the NC Tenku RX PTCA balloon catheter over issues with removing the protective balloon sheath which can result in issues inflating or deflating the balloon. Risks associated with inflation and deflation issues include air embolism, thrombosis, myocardial infarction and may require additional interventi...
Source: Mass Device - April 21, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Catheters Recalls Abbott Source Type: news

Forty years, 1 procedure, millions of lives saved
(Society for Cardiovascular Angiography and Interventions) This year, the Society for Cardiovascular Angiography and Interventions (SCAI) will be celebrate the 40th anniversary of coronary angioplasty, a procedure that revolutionized the way heart disease is treated and has since saved millions of lives around the world. This celebration will occur in conjunction with the Society's 40th anniversary at the SCAI 2017 Scientific Sessions (SCAI 2017) in New Orleans May 10-13. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 13, 2017 Category: Global & Universal Source Type: news

Cardiovascular Systems launches combined Diamondback 360, DES trial
Cardiovascular Systems (NSDQ:CSII) said today it enrolled the 1st patient in the Eclipse clinical trial of its Diamondback 360 coronary orbital atherectomy system. The St. Paul, Minn.-based company is looking to enroll 2,000 patients in the trial which aims to explore the use of the Diamondback 360 device for treating patients with severely calcified coronary lesions prior to drug-eluting stent placement. A control group will consist of patients treated with conventional angioplasty, including specialty balloons, prior to DES placement, the comapny said. The trial’s primary endpoint will be post-procedural minim...
Source: Mass Device - March 29, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Catheters Clinical Trials Cardiovascular Systems Inc. Source Type: news

Teleflex (TFX) Announces 510(k) Clearance and U.S. Launch of Spectre(TM) Guidewire
WAYNE, Pa.--(Healthcare Sales & Marketing Network)--Teleflex Incorporated (TFX), a leading global provider of medical technologies for critical care and surgery, has announced 510(k) clearance by the Food and Drug Administration and U.S. commercial launch ... Devices, Interventional, Cardiology, FDA, Product Launch Teleflex, Spectre Guidewire, percutaneous coronary intervention (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 14, 2017 Category: Pharmaceuticals Source Type: news

New Study Finds Abiomed Impella(R) Heart Pump Reduces Injury to Kidneys During High-Risk Percutaneous Coronary Intervention
DANVERS, Mass., March 09, 2017 -- (Healthcare Sales & Marketing Network) -- A new study published in Circulation Research finds use of hemodynamic support with Impella® 2.5 heart pump during high-risk percutaneous coronary intervention (HRPCI) can redu... Devices, Interventional, Cardiology Abiomed, Impella, Heart Pump, percutaneous coronary intervention (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 9, 2017 Category: Pharmaceuticals Source Type: news

Bivalirudin in Briefer PCI May Boost Stent Thrombosis Risk Bivalirudin in Briefer PCI May Boost Stent Thrombosis Risk
Shorter percutaneous coronary intervention (PCI) procedures are associated with an increased risk of acute stent thrombosis (AST) in patients treated with bivalirudin, according to a secondary analysis of a randomized clinical trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 7, 2017 Category: Consumer Health News Tags: Emergency Medicine News Source Type: news

Daiichi Sankyo begins enrolment in Phase IIIb trial of edoxaban to treat atrial fibrillation
Japanese-based pharmaceutical firm Daiichi Sankyo has begun enrolment in the Phase IIIb ENTRUST-AF PCI clinical trial of edoxaban for the treatment of atrial fibrillation patients who have undergone percutaneous coronary intervention (PCI) with stent … (Source: Drug Development Technology)
Source: Drug Development Technology - March 7, 2017 Category: Pharmaceuticals Source Type: news

FOXTROT < sup > ® < /sup > NC PTCA Balloon Catheter Gains Regulatory Approval in Mexico
(Source: Microport News Release)
Source: Microport News Release - February 25, 2017 Category: Medical Equipment Source Type: news

Study reveals ways to improve outcomes, reduce costs for common heart procedure
(Washington University School of Medicine) Hospitals can improve patient care and reduce costs associated with coronary angioplasty if cardiologists perform more of these procedures through an artery in the wrist and if they take steps to discharge such patients on the same day, according to a new study led by Washington University School of Medicine in St. Louis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 21, 2017 Category: Global & Universal Source Type: news

Radial access, same-day cardiac procedure could save $300 million annually
(American College of Cardiology) If hospitals can perform more transradial, same-day percutaneous coronary intervention, or PCIs, not only will patients benefit because it is associated with have less complications, but collectively, hospitals across the U.S. could save $300 million each year, according to research published today in JACC: Cardiovascular Interventions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 20, 2017 Category: Global & Universal Source Type: news

Medtronic launches Signia stapler
Medtronic (NYSE:MDT) said today it launched its Signia stapling system in the US, Western Europe and Japan. The newly launched stapler from the Fridley, Minn.-based company includes Adaptive Firing technology which adjusts the stapler’s speed based on tissue variability measurements for more consistent staple lines. The device also includes 1-hand staple firing to allow for more operator freedom during procedures. “In my experience to date, I believe the articulation, rotation and firing of the Signia system provides an important new option in the performance of minimally invasive surgical procedures. Its abili...
Source: Mass Device - February 16, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Surgical Medtronic Source Type: news

National Pharmaceutical Pricing Authority slashes stent prices by up to 85 per cent
This comes as a huge relief to lakhs of patients who have to undergo coronary angioplasty to insert stents to open up clogged arteries. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 14, 2017 Category: Pharmaceuticals Source Type: news

MassDevice.com +5 | The top 5 medtech stories for February 12, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. AcelRx touts Dsuvia data for burn victims AcelRx Pharmaceuticals said today that it plans to present data from a study evaluating its Dsuvia pain reliever in patients with moderate-to-severe acute pain resulting from trauma or ...
Source: Mass Device - February 13, 2017 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

MassDevice.com +5 | The top 5 medtech stories for February 13, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. AcelRx touts Dsuvia data for burn victims AcelRx Pharmaceuticals said today that it plans to present data from a study evaluating its Dsuvia pain reliever in patients with moderate-to-severe acute pain resulting from trauma or ...
Source: Mass Device - February 13, 2017 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Medtronic launches DxTerity, TRA-line of radial access devices for PCIs
Medtronic (NYSE:MDT) today announced a slew of new percutaneous coronary intervention devices it added to its portfolio, including the DxTerity diagnostic angiography catheter line, the DxTerity TRA, InTRAkit transradial devices and the TRAcelet compression device. The Fridley, Minn.-based company said all of the items have already received FDA clearance in the US and CE Mark approval in the European Union for use in diagnostic cardiac catheterization procedures and percutaneous coronary interventions. Medtronic’s DxTerity and DxTerity TRA diagnostic catheters are designed to help determine whether revasculariza...
Source: Mass Device - February 13, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Cardiovascular Catheters Medtronic Source Type: news

Abiomed gains after Abbott tables HeartMate PHP program
Abiomed (NSDQ:ABMD) shares closed up more than 5% yesterday as investors reacted to reports that Abbott (NYSE:ABT) paused its HeartMate PHP program in Europe. Abbott, which acquired the Thoratec line of HeartMate cardiac assist devices when it paid $25 billion for St. Jude Medical (NYSE:STJ) last month, reportedly advised physicians last week that it’s temporarily halting its Shield II clinical trial for the HeartMate PHP pump due to an issue with its catheter. Abbott said it “temporarily paused the HeartMate PHP Shield II IDE clinical trial as well as shipment and implantation of ...
Source: Mass Device - February 7, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiac Assist Devices Clinical Trials Wall Street Beat Abbott Abiomed Inc. Source Type: news